ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Price-to-Tangible-Book : 7.43 (As of May. 25, 2024)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Price-to-Tangible-Book?

As of today (2024-05-25), ImmuneOnco Biopharmaceuticals (Shanghai)'s share price is HK$14.60. ImmuneOnco Biopharmaceuticals (Shanghai)'s Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was HK$1.97. Hence, ImmuneOnco Biopharmaceuticals (Shanghai)'s Price to Tangible Book Ratio of today is 7.43.

The historical rank and industry rank for ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Tangible-Book or its related term are showing as below:

HKSE:01541' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.21 Med: 15.21 Max: 15.21
Current: 7.41

During the past 3 years, ImmuneOnco Biopharmaceuticals (Shanghai)'s highest Price to Tangible Book Ratio was 15.21. The lowest was 7.21. And the median was 15.21.

HKSE:01541's Price-to-Tangible-Book is ranked worse than
82.75% of 1223 companies
in the Biotechnology industry
Industry Median: 2.78 vs HKSE:01541: 7.41

A closely related ratio is called PB Ratio. As of today, ImmuneOnco Biopharmaceuticals (Shanghai)'s share price is HK$14.60. ImmuneOnco Biopharmaceuticals (Shanghai)'s Book Value per Sharefor the quarter that ended in Dec. 2023 was HK$2.19. Hence, ImmuneOnco Biopharmaceuticals (Shanghai)'s P/B Ratio of today is 6.68.

ImmuneOnco Biopharmaceuticals (Shanghai) Price-to-Tangible-Book Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Price-to-Tangible-Book Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Price-to-Tangible-Book

15.21

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Tangible-Book	-	-	-	-	15.21

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Tangible-Book

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Tangible-Book falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) Price-to-Tangible-Book Calculation

ImmuneOnco Biopharmaceuticals (Shanghai)'s price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	14.60	/	1.966
	=	7.43

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

ImmuneOnco Biopharmaceuticals (Shanghai) Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines